Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
FDMT Stock Chart & Stats
$11.97
-$0.14(-2.20%)
At close: 4:00 PM EST
$11.97
-$0.14(-2.20%)
Day’s Range― - ―
52-Week Range$2.24 - $12.34
Previous CloseN/A
Volume165.32K
Average Volume (3M)836.82K
Market Cap
$559.03M
Enterprise Value-$62.66M
Total Cash (Recent Filing)$293.23M
Total Debt (Recent Filing)$23.08M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 05, 2025EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding46,702,470
10 Day Avg. Volume957,038
30 Day Avg. Volume836,820
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.11
Enterprise Value/Revenue-1.90K
Enterprise Value/Gross Profit17.22
Enterprise Value/Ebitda0.28
Forecast
1Y Price Target
$34.06Price Target Upside184.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe accelerated enrollment of 4FRONT-1 reflects the high interest for gene therapies for wAMD.
Financial Stability$417M in cash expected to fund operations into 2028.
Product Differentiation4D-150 is well positioned to be clearly differentiated given its intravitreal administration, highly favorable safety profile, and strong efficacy data showing over 80% treatment burden reduction in wAMD patients.
Bears Say
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $2.23 and its highest was $12.34 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $559.03M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 6 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.727 by -$0.253.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -0.99.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 46,702,470 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.727. Following the earnings report the stock price went down -1.776%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Currently, no hedge funds are holding shares in FDMT
4D Molecular Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.06 (184.54% Upside)
$34.06 (184.54% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 43.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $32.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 13.0%
Last 30 Days ▲ 13.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.67%
12-Months-Change
Fundamentals
Return on Equity
-38.87%
Trailing 12-Months
Asset Growth
-23.62%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
FDMT Stock 12 Month Forecast
Average Price Target
$34.06
▲(184.54% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Design Therapeutics
―
Immuneering
―
Aura Biosciences Inc
―
Ownership Overview
12.46% Insiders
14.56% Mutual Funds
1.76% Other Institutional Investors
58.93% Public Companies and
Individual Investors